What's Happening?
Arcutis Biotherapeutics has announced that its product ZORYVE has received the 2025 Best of Beauty Breakthrough Award from Allure magazine. ZORYVE is the first FDA-approved medication for eczema, plaque psoriasis, and seborrheic dermatitis to win this award. The product is recognized for its innovative approach in dermatology, offering a steroid-free topical treatment that is safe, well-tolerated, and effective across multiple inflammatory skin conditions. ZORYVE is available in cream and foam formulations, designed for use on diverse skin and hair types.
Why It's Important?
The recognition of ZORYVE by Allure magazine underscores its impact in the field of dermatology, highlighting its role in transforming skincare treatment options. As the number one prescribed branded topical therapy for major inflammatory dermatoses, ZORYVE offers a significant advancement in patient care, providing a safe alternative to traditional steroid treatments. This award reflects the growing importance of innovative dermatological solutions in addressing unmet patient needs and improving quality of life.
